Single arm, single center clinical study of intensity modulated radiation therapy combined with anlotinib in the treatment of advanced non-small cell lung cancer

Intensity modulated radiation therapy combined with anlotinib in the treatment of advanced non-small cell lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043854

Enrollment

Unknown

Registered

2021-03-04

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

experimental group:Standard second-line treatment of alotinib plus radiotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Stage IV non-small cell lung cancer diagnosed by pathology or cytology; 2. Progress of standard first-line treatment; 3. Aged 18-80 years; 4. With measurable lesions (by RECIST 1.1); 5. ECoG PS: 0-1; 6. There was no contraindication to radiotherapy; 7. The function of main organs met the treatment requirements; 8. The patients voluntarily participated in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with central, cavitary squamous cell lung cancer or non-small cell lung cancer with hemoptysis (> 50 ml / day); 2. Patients with brain metastases accompanied with symptoms or symptom control time less than 2 months; 3. Patients whose tumor has invaded important blood vessels or who are likely to have massive hemorrhage during the follow-up study; 4. Patients with any signs or history of bleeding.

Design outcomes

Primary

Measure	Time frame
PFS;ORR;	—

Countries

China

Contacts

Public ContactChen Xiaoliang

General Hospital of Pingmei Shenma Medical Group

39703600@qq.com+86 15837532579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026